Nephrosis: Clinical Trials

8 trials for Nephrosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 terminated. 8 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 28Terminated 8
Phase 31Terminated 1

Follow Nephrosis: new trials by email Literature Review of Nephrosis trials Research Report on Nephrosis

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)
VB119 - Minimal Change Disease, Focal Segmental Glomerulosclerosis
Phase 2TerminatedTenet Medicines12022-05-032024-04-22
An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases
GFB-887 - Kidney Diseases, Glomerulosclerosis
Phase 2TerminatedGoldfinch Bio, Inc.312021-07-272022-11-15
A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
GFB-887, Placebo - Kidney Diseases, Diabetic Nephropathies
Phase 2TerminatedGoldfinch Bio, Inc.962020-07-282022-11-15
Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome
Rituximab Biosimilar, Mycophenolate Mofetil - Nephrotic Syndrome Steroid-Dependent
Phase 2TerminatedIstituto Giannina Gaslini302019-07-012020-09-14
Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome
Alirocumab, Alirocumab placebo, Atorvastatin - Nephrotic Syndrome
Phase 2TerminatedGloria Vega32017-01-012022-08-19
Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome.
Enoxaparin - Nephrotic Syndrome
Phase 2 / Phase 3TerminatedMilitary Institute od Medicine National Research Institute652015-10-012023-01-30
Ofatumumab in Children With Drug Resistant Idiopathic Nephrotic Syndrome
Ofatumumab, Placebo - Nephrotic Syndrome
Phase 2TerminatedIstituto Giannina Gaslini132015-07-012020-07-29
Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia Secondary to Nephrotic Syndrome
Atorvastatin, Placebo - Nephrotic Syndrome, Hyperlipidemia
Phase 2TerminatedNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)51998-10-012017-09-15

Narrower conditions

Nephrotic Syndrome (5)  ·  Glomerulonephritis (2)  ·  Glomerulosclerosis, Focal Segmental (2)  ·  Kidney Diseases (2)  ·  Nephritis (2)  ·  Nephrosis, Lipoid (2)  ·  Diabetes Complications (1)  ·  Diabetes Mellitus (1)  ·  Diabetic Nephropathies (1)  ·  Dyslipidemias (1)  ·  Endocrine System Diseases (1)  ·  Hyperlipidemias (1)  ·  Proteinuria (1)  ·  Rare Diseases (1)

Broader conditions

Female Urogenital Diseases (8)  ·  Female Urogenital Diseases and Pregnancy Complications (8)  ·  Male Urogenital Diseases (8)  ·  Urogenital Diseases (7)  ·  Urologic Diseases (7)  ·  Kidney Diseases (6)  ·  Metabolic Diseases (3)  ·  Nutritional and Metabolic Diseases (3)  ·  Lipid Metabolism Disorders (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Cardiovascular Diseases (1)  ·  Disease Attributes (1)  ·  Dyslipidemias (1)  ·  Embolism and Thrombosis (1)

Interventions

Atorvastatin (2)  ·  Enoxaparin (1)  ·  Mycophenolic Acid (1)  ·  Saline Solution (1)  ·  alirocumab (1)  ·  ofatumumab (1)

Sponsors

Goldfinch Bio, Inc. (2)  ·  Istituto Giannina Gaslini (2)  ·  Gloria Vega (1)  ·  Military Institute od Medicine National Research Institute (1)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)  ·  Tenet Medicines (1)

Countries

United States (5)  ·  Italy (2)  ·  Poland (1)

Top investigators

Gianmarco Ghiggeri, MD (2)  ·  Anna Matyjek, MD, PhD (1)  ·  Gloria L Vega, PhD (1)  ·  Michael Concepcion, MD (1)  ·  Ronald Hogg (1)  ·  Yin Oo, MD (1)

Results publications

PMID 31993781, PMID 33616641, PMID 34884411, PMID 38724717, PMID 39513526, PMID 40337980

NIH funding

R21DK053611 (1)